Abstracts Archive - Page 298 of 2607 - ACR Meeting Abstracts

Abstract Number: 1677 • ACR Convergence 2024
Safety and Efficacy of FNS007, a Non-T Cell Receptor Contacting Peptide, for Patients with Active Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial
Ru Li¹, Xing Sun¹, Suping Niu², Xiaolin Sun¹, Guimin Zheng³, Meilu Liu³, Jiyang Lv⁴, Gengmin Zhou⁴, Gang Yuan⁵, Yujin Ye⁵, Shuang Wang⁵, Pingfei Fang⁶, Qi Tang⁶, Jin Kang⁶, Xiaoyue Li⁷, Chao Sun⁷, Song Zhang⁷, Yongjun Mei⁷, Jian Wang⁷, He Su⁷, Lijing Huang⁸, Chenhui Li⁸, Chao Liu⁸, Fengxiao Zhang³, Qingwen Wang⁴, Niansheng Yang⁵, Fen Li⁶, Linjie Chen⁷, Yi Fang² and Zhanguo Li⁹, ¹Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China, ²Clinical Trial Institution, Peking University People’s Hospital, Beijing, China, ³Department of Rheumatology and Immunology, Hebei General Hospital, Shijiazhuang, Hebei, China (People's Republic), ⁴Department of Rheumatism and Immunology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China (People's Republic), ⁵Department of Rheumatology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China (People's Republic), ⁶Department of Rheumatology and Immunology, the Second Xiangya Hospital of Central South University, Changsha, Hunan, China (People's Republic), ⁷Department of Rheumatology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ⁸Hebei Fitness Biotechnology Limited Company, Shijiazhuang, Hebei, China (People's Republic), ⁹Peking univeristy people's hospital, Beijing, China
Background/Purpose: Long-term drug-free remission is an unmet need for the management of rheumatoid arthritis (RA), which might be achieved by restoring antigen-specific immune tolerance. Autoantigenic…
Abstract Number: 1626 • ACR Convergence 2024
Intracranial Giant Cell Arteritis: A Comprehensive Systematic Review
Sagar Patel¹, Iva Okaj², Jessica Scott³, Sukhreet Atwal³, Colin Stark³, Rabia Tahir³, Nader Khalidi² and Mats Junek², ¹McMaster University, Brampton, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³McMaster University, Hamilton, Canada
Background/Purpose: Giant cell arteritis is being increasingly recognized to occur in intracranial vessels. The clinical significance of intracranial GCA (ICGCA) is unknown; previous cases have…
Abstract Number: 1658 • ACR Convergence 2024
IGF1 Drives Wnt-induced Joint Damage and Is a Therapeutic Target for Osteoarthritis
Ana Escribano-Nunez¹, Frederique Cornelis², Astrid Deroover¹, An Sermon¹, Frederic Cailotto³, Rik Lories² and Silvia Monteagudo⁴, ¹KU Leuven, Leuven, Vlaams-Brabant, Belgium, ²Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, Leuven, Belgium, ³Université Lorraine, Nancy, Lorraine, France, ⁴KU Leuven, Leuven, Belgium
Background/Purpose: Osteoarthritis is the most common joint disease and a global leading cause of pain and disability. Its multifactorial etiology includes excessive activation of Wnt…
Abstract Number: 1673 • ACR Convergence 2024
Assessing the Feasibility of a Mediterranean-Style Diet for Patients with Rheumatoid Arthritis in a Racially and Culturally Diverse Population Across the United States
Chelsea Thompson¹, iazsmin Ventura¹, Cuoghi Edens², Tamiko Katsumoto³ and Sowmya Popuri⁴, ¹Section of Rheumatology, University of Chicago, Chicago, IL, ²Section of Pediatric Rheumatology, Section of Rheumatology, University of Chicago, Chicago, IL, ³Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁴Section of Internal Medicine, Loyola Medicine MacNeal, Maywood, IL
Background/Purpose: In 2023, the American College of Rheumatology published a conditional recommendation for patients living with Rheumatoid Arthritis to follow a “Mediterranean style” diet. However,…
Abstract Number: 1568 • ACR Convergence 2024
Distribution of Proteinuria in Scleroderma Renal Crisis: A Multi-Center Study
Arifa Javed¹, Lilit Grigoryan², Alex Luta³, Sumbal Wajid², Lee Shapiro⁴, Virginia Steen⁵ and Swati Mehta⁶, ¹Albany Medical Center, Rensselaer, NY, ²Albany Medical Center, Albany, NY, ³MedStar Georgetown University Hospital, Rockville, MD, ⁴Albany Medical College, Stillwater, NY, ⁵Georgetown University School of Medicine, Washington, DC, ⁶Division of Nephrology, Department of Medicine, Albany Medical Center, Albany, NY
Background/Purpose: Scleroderma renal crisis (SRC) is a rare but life-threatening complication of systemic sclerosis (SSc), characterized by malignant hypertension and acute kidney injury (AKI). Proteinuria when present at the time of…
Abstract Number: 1637 • ACR Convergence 2024
Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease: Relation with Neoplasms and Role as a Paraneoplastic Syndrome
Pablo Muñoz Martínez¹, Claudia Fernandez Ruiz², Elena Grau García³, Samuel Leal Rodriguez³, José Ivorra-Cortés⁴, Carmen Riesco Barcena⁵, Anderson Huaylla Quispe⁵, Laura Mas Sánchez⁶, Daniel Ramos Castro⁵, Alba Torrat noves⁷, Iago Alcantara Alvarez⁸, Belén Villanueva Mañés⁸, Miguel Simeo Vinaixa⁸, Andrés Pérez Hurtado⁵ and Jose A Román-Ivorra⁹, ¹Hospital Universitario y Politècnico La Fe, Sagunto, Spain, ²Escuela de Doctorado. UCV, Valencia, Comunidad Valenciana, Spain, ³HUP La Fe, Valencia, Spain, ⁴Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, ⁵Rheumatology Department. HUP La Fe, Valencia, Spain, ⁶Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, ⁷Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, ⁸Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁹Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: The dysregulation of the immune system inherent in inflammatory diseases may contribute to the development of neoplasms. However, the relationship between the giant cell…
Abstract Number: 1554 • ACR Convergence 2024
Belimumab Increases SLE Responder Index-4 Response Rates versus Placebo in Early Active Systemic Lupus Erythematosus: A Large Integrated Analysis of Belimumab Trials
Karen Costenbader¹, Joan Merrill², Marta Mosca³, Holly Quasny⁴, Christine Henning⁵, Steven Bloom⁶, Julia Harris⁶, Ciara O’Shea⁷, Tatsuya Atsumi⁸ and Ronald van Vollenhoven⁹, ¹Brigham and Women’s Hospital, Division of Rheumatology, Inflammation and Immunity, Harvard Medical School, Boston, MA, ²Oklahoma Medical Research Foundation, Arthritis & Clinical Immunology Program, Oklahoma City, OK, ³University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, ⁴GSK, Clinical Sciences, Durham, NC, ⁵GSK, Global Medical Affairs, Durham, NC, ⁶GSK, Immunology Biostatistics, Brentford, United Kingdom, ⁷GSK, Rheumatology, Global Medical Affairs, Dublin, Ireland, ⁸Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ⁹Amsterdam Rheumatology and Immunology Center and Amsterdam University Medical Centers, Department of Rheumatology, Amsterdam, Netherlands

Background/Purpose: There are benefits of early treatment for autoimmune diseases; however, data are not available for patients (pts) with SLE as there is no definition…
Abstract Number: 1669 • ACR Convergence 2024
Will Investigators Enroll? A Vignette Study to Gauge Investigator Equipoise in a Trial of Surgery vs. Nonoperative Therapy in Subjects with Meniscal Tear and Persistent Pain Following Physical Therapy
Jeffrey Katz¹, Faith Selzer², Katharine Fox³, Jon Dhani³, Kyna Long³, Andrea Carland⁴, Tiffany Thavison⁴, Leslie Bisson⁴, Morgan Jones³, Katherine Krupa³ and Nomi Weiss-laxer⁵, ¹Brigham and Women's Hospital, Brookline, MA, ²Brigham and Women's Hospital, Amesbury, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴University at Buffalo, Buffalo, NY, ⁵U, Buffalo, NY
Background/Purpose: Clinician investigators may be unwilling to enroll all eligible subjects into randomized controlled trials (RCTs) because they feel certain subjects would benefit more from…
Abstract Number: 1565 • ACR Convergence 2024
Prevalence and Risk Factors of Lower Extremities Arterial Disease in Systemic Sclerosis: Preliminary Data from a Single Centre Multidisciplinary Study
Maria-Grazia Lazzaroni¹, Paolo Baggi², Liala Moschetti¹, Eleonora Pedretti³, Elda Piovani¹, Claudia Barison¹, Emma Manzoni⁴, Franco Franceschini¹, Stefano Bonardelli² and Paolo Airò¹, ¹Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ²Vascular Surgery Unit, ASST Spedali Civili of Brescia, University of Brescia, Italy, Brescia, Italy, ³Scleroderma Unit, Rheumatology Unit, ERN ReCONNET, ASST Spedali Civili and University of Brescia; Italy, Brescia, Italy, ⁴University of Brescia, Brescia, Italy
Background/Purpose: Microvascular changes represent a key step of pathogenic process in Systemic Sclerosis (SSc). However, SSc has been demonstrated to carry an increased risk of…
Abstract Number: 1671 • ACR Convergence 2024
Are Patient-reported Outcomes for Dactylitis, Uveitis, Psoriatic Skin and Nail Disease Valid in Patients with Psoriatic Arthritis?
Louise Nielung¹, Merete Hetland², Lone Skov³, Hans Albert Frandsen⁴, Lene Dreyer⁵ and Bente Glintborg⁶, ¹Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ²DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark, Glostrup, Denmark, ³Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Gentofte, Denmark, ⁴Patient Partner, Frederiksberg, Denmark, ⁵Department of Rheumatology, Aalborg UnIversity Hospital, København, Denmark, ⁶DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark
Background/Purpose: In routine care, Danish patients with psoriatic arthritis (PsA) are monitored in DANBIO, a nationwide clinical registry1. Patients enter patient-reported outcomes (PROs) online before…
Abstract Number: 1638 • ACR Convergence 2024
Calprotectin, a Mechanistically Informed Biomarker for Clinically Isolated Aortitis
Katarina Kmetova¹, Emily Chong², NaveenKumar Somanathapura K³, Kavya Sugur², Lyndsay Kluge², Srilakshmi Yalavarthi³, Julia Ford³, Ora Singer⁴ and Yu Zuo³, ¹Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann arbor, Ann arbor, MI, ³University of Michigan, Ann arbor, MI, ⁴University of Michigan, Huntington Woods, MI
Background/Purpose: Clinically isolated aortitis (CIA) is aortitis in patients without evidence of systemic disease, infection, or involvement of other vascular territories. CIA is discovered incidentally…
Abstract Number: 1574 • ACR Convergence 2024
Therapeutic Strategy in Patients with Mixed Connective Tissue Disease: A Multicenter Retrospective Study in the French MCTD Cohort
Kevin Chevalier¹, Benjamin Thoreau², Marc Michel³, Bertrand Godeau⁴, Christian AGARD⁵, Thomas Papo⁶, Karim Sacré⁶, Raphaele Seror⁷, Xavier Mariette⁸, Patrice Cacoub⁹, Ygal Benhamou¹⁰, Hervé Levesque¹⁰, Cécile Goujard¹¹, Olivier Lambotte¹¹, Bernard Bonnotte¹², Maxime SAMSON¹³, Felix Ackermann¹⁴, Jean Schmidt¹⁵, Pierre Duhaut¹⁶, Jean-Emmanuel Kahn¹⁷, Thomas Hanslik¹⁷, Nathalie Costedoat-chalumeau¹⁸, Benjamin Terrier¹⁹, Alexis Régent²⁰, bertrand Dunogue², Pascal cohen²¹, Veronique LE GUERN²², Eric Hachulla²³, Luc Mouthon² and Benjamin Chaigne²⁴, ¹Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France, Paris, France, ²Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ³2. Department of Internal Medicine, Henri-Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil (UPEC), Créteil, France., Créteil, France, ⁴Department of Internal Medicine, Henri-Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil (UPEC), Créteil, France., Créteil, France, ⁵Nantes University Hospital, Nantes, France, ⁶Université Paris Cité, Paris, France, ⁷Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, ⁸Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ⁹Sorbonne Université, Paris, ¹⁰Department of Internal Medicine, CHU de Rouen, UniRouen, Rouen, France., Rouen, France, ¹¹Université Paris Saclay, Department of Internal Medicine and clinical immunology, Bicêtre hospital, Assistance Publique-Hôpitaux de Paris, UMR1184 Inserm, CEA, Le Kremlin Bicêtre, France, Kremlin-Bicêtre, France, ¹²Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France., Dijon, France, ¹³Dijon University Hospital, Dijon, France, ¹⁴Department of Internal Medicine, Foch Hospital, Suresnes, France., Suresnes, France, ¹⁵Department of Internal Medicine and RECIF, Amiens University Hospital, Université Picardie Jules Verne, Amiens, France., Amiens, France, ¹⁶Department of Internal Medicine and RECIF, Amiens-Picardie University Hospital, AMIENS, France, ¹⁷Department of Internal Medicine, Ambroise Paré Hospital, Assistance Publique - Hôpitaux de Paris, Université de Versailles Saint-Quentin-en-Yvelines, Boulogne-Billancourt, France, Boulogne Billancourt, France, ¹⁸University Paris Cité, Paris, France, ¹⁹Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ²⁰National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ²¹National Referral Center For Rare Systemic Autoimmune Diseases, Paris, Ile-de-France, France, ²²Cochin hospital, Paris, France, ²³Department of Internal Medicine and clinical immunology, North-West National Reference Center for Rare Systemic Autoimmune Diseases iques et Auto-Immunes Rares du Nord-Ouest, Hôpital Claude Huriez, Université de Lille, France, Lille, France, ²⁴Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France
Background/Purpose: Mixed connective tissue disease (MCTD) is a rare systemic disorder that belongs to connective tissue diseases (CTD). Few studies are available on MCTD treatment.…
Abstract Number: 0135 • ACR Convergence 2024
Rheumatoid Arthritis Associated Risk of Venous Thromboembolism Is Not Dependent on Disease Duration: United Kingdom Based Population Study
James Galloway¹, Victoria Basey², Saqib Rana³, Simon de Lusignan⁴ and Maya H. Buch⁵, ¹Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ²Pfizer UK, Tadworth, United Kingdom, ³Pfizer, Tadworth, United Kingdom, ⁴Royal College of General Practitioners Research and Surveillance Centre, Oxford, United Kingdom, ⁵Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom
Background/Purpose: Risk of venous thromboembolism (VTE) is higher in patients with rheumatoid arthritis (RA) compared to the general population; however whether this risk changes with…
Abstract Number: 0189 • ACR Convergence 2024
Racial Discrimination Among African American Women with and Without Systemic Lupus Erythematosus (SLE)
Jessica Browder¹, Paula Ramos², Diane Kamen², Bethany Wolf², S. Sam Lim³, Lori Ann Ueberroth² and Lusawasra King², ¹Florida State University, Tallahassee, FL, ²Medical University of South Carolina, Charleston, SC, ³Emory University, Atlanta, GA
Background/Purpose: Black or African American women are disproportionately affected by SLE but remain underrepresented in research studies. To further knowledge about this health disparity group,…
Abstract Number: 0136 • ACR Convergence 2024
Demographic and Clinical Characteristics of Patients with SLE Across 5 Registries – the LupusNet Federated Data Network
Federico Zazzetti¹, Urbano Sbarigia², William Giovanini³, Claire Blacketer⁴, Michel van Speybroeck⁵, Teresa A. Simon⁶, Guo Li³, Chetan S. Karyekar⁴, Reyhan Sonmez⁷, Manuel Ugarte-Gil⁸, RV, Gamboa-Cardenas⁹, Victor Pimentel-Quiroz¹⁰, Guillermo Pons-Estel¹¹, Bernardo Pons-Estel¹², Rosana Quintana¹³, Veronica Saurit¹⁴, ODIRLEI MONTICIELO¹⁵, Katiuzka Zuñiga Corrales¹⁶, Jorge Esquivel-Valerio¹⁷, Martin Rebella¹⁸, Cecilia Pisoni¹⁹, Francinne Machado Ribeiro²⁰, Carlos Núñez-Álvarez²¹, Kaleb Michaud²², Patricia Katz²³, Rangi Kandane-Rathnayake²⁴, Eric Morand²⁵, Worawit Louthrenoo²⁶, Yi-Hsing Chen²⁷, Jiacai Cho²⁸, Laniyati Hamijoyo²⁹, Shue Fen Luo³⁰, Yeong-Jian Jan Wu³⁰, Sandra Navarra³¹, Sargunan Sockalingam³², Masayoshi Harigai³³, Zhuoli Zhang³⁴, BMDB Basnayake³⁵, Madelynn Chan³⁶, Tsutomu Takeuchi³⁷, Sang-Cheol Bae³⁸, Fiona Goldblatt³⁹, Sean O'Neill⁴⁰, Kristine (Pek Ling) Ng⁴¹, Yih Jia Poh⁴², Nicola Tugnet⁴³, Sunil Kumar⁴⁴, Michael Tee⁴⁵, Yoshiya Tanaka⁴⁶ and Chak Sing. Lau⁴⁷, Alberta Hoi⁴⁸, Mandana Nikpour⁴⁹, Mark Sapsford⁵⁰, Íñigo Rúa-Figueroa⁵⁰, José María Pego-Reigosa⁵¹, María Galindo-Izquierdo⁵², Jaime Calvo-Alén⁵³, Antonio Fernández-Nebro⁵⁴, Raúl Menor Almagro⁵⁵ and Frederic Lavie⁵⁶, ¹Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ²Johnson & Johnson Innovative Medicine, Brussels, Belgium, ³The Janssen Pharmaceutical Companies of Johnson & Johnson, Titusville, NJ, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Pharmaceutica, Beerse, Belgium, ⁶Physicians Research Center, LLC, Toms River, NJ, ⁷EFOR-CVO Life Sciences Consultancy, Basel, Switzerland, ⁸Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas. Universidad Científica del Sur. Lima. Perú Servicio de Reumatología. Hospital Guillermo Almenara Irigoyen-EsSalud, Lima, Peru, ⁹Universidad Científica del Sur, Lima, Lima, Peru, ¹⁰Universidad Científica del Sur/Hospital Nacional Guillermo Almenara Irigoyen, Magdalena del Mar, Peru, ¹¹Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ROSARIO, Santa Fe, Argentina, ¹²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, ¹³Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ¹⁴hospital privado universitario de cordoba, Córdoba, Argentina, ¹⁵HOSPITAL DE CLINICAS DE PORTO ALEGRE, PORTO ALEGRE, Rio Grande do Sul, Brazil, ¹⁶Hospital Cayetano Heredia. Universidad Peruana Cayetano Heredia, Lima, Peru, ¹⁷Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, ¹⁸Unidad Enfermedades Autoinmunes Sistemicas, Clinica Medica C-Hospital de Clinicas, UDELAR Montevideo, Montevideo, Uruguay, ¹⁹CEMIC, Buenos Aires, Argentina, ²⁰Hospital Universitario Pedro Ernesto, UERJ, Rio De Janeiro, Brazil, Rio de Janeiro, Brazil, ²¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, CDMX, Mexico, Mexico, Mexico, ²²University of Nebraska Medical Center, Omaha, NE, ²³University of California San Francisco, San Francisco, CA, ²⁴Monash University, Clayton, Victoria, Australia, ²⁵School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ²⁶Chiang Mai University, Chang Wat Chiang Mai, Thailand, ²⁷Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ²⁸National University Hospital, Kent Ridge, Singapore, ²⁹University of Padjadjaran, Sumedang Regency and Bandung, Indonesia, ³⁰Chang Gung Memorial Hospital, Taoyuan City, Taiwan (Republic of China), ³¹University of Santo Tomas, Manila, Philippines, ³²University of Malaya Medical Centre, Kuala Lumpur, Malaysia, ³³Tokyo Women's Medical University, Tokyo, Japan, ³⁴Peking University First Hospital, Beijing, China, ³⁵Teaching Hospital, Kandy, Sri Lanka, ³⁶Tan Tock Seng Hospital, Singapore, Singapore, ³⁷Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ³⁸Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³⁹Flinders Medical Centre, Adelaide, Australia, ⁴⁰Liverpool Hospital; Royal North Shore Hospital; University of New South Wales and the University of Sydney, Sydney, New South Wales, Australia, ⁴¹Health New Zealand Waitemata, Te Whatu Ora (North Shore Hospital), Auckland, New Zealand, ⁴²SingHealth, Singapore, Singapore, ⁴³Auckland District Health Board, Auckland, New Zealand, ⁴⁴Health New Zealand Counties Manukau, Te Whatu Ora (Middlemore Hospital), Auckland, New Zealand, ⁴⁵University of the Philippines, Manila, Philippines, ⁴⁶Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁴⁷University of Hong Kong, Pok Fu Lam, Hong Kong, ⁴⁸Monash Health, Monash University, Melbourne, AU, Melbourne, Victoria, Australia, ⁴⁹The University of Sydney, Melbourne, Victoria, Australia, ⁵⁰Middlemore Hospital, Auckland, New Zealand, ⁵⁰Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, ⁶Galicia Health Service (SERGAS), Vigo, Spain, ⁵²Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁵³Department of Rheumatology, Hospital Araba, Vitoria, Pais Vasco, Spain, ⁵⁴Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Andalucia, Spain, ⁵⁵Department of Rheumatology, Hospital Jerez de la Frontera, Jerez de la Frontera, Spain, ⁵⁶Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with a broad range of clinical manifestations and a high unmet need across patient populations. Real-world…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].